EUCTR2006-005520-16-GB进行中（未招募）1 期
A multi-center, randomized, double-blind, placebo-controlled phase III trial omparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) - MAI
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 787
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients previously randomized to the BO20603 study (MAIN) and who have received any cycle of study treatment prior to termination of bevacizumab treatment by 31 May 2010.
- •Previously randomized patients providing written informed consent to continue study participation according to this modified version of the study protocol (version D).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients not randomized to the BO20603 study prior to 01 June 2010 following the DSMB recommendation which became effective on 31 May 2010.
- •Previously randomized patients who are not willing to sign the amended informed consent.
研究者
相似试验
进行中（未招募）
1 期
未命名试验Persistent AsthmaEUCTR2010-018481-22-NLovartis Pharma Services AG192
进行中（未招募）
不适用
A sleep laboratory study to investigate the safety and efficacy of the rotigotine skin patch in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysisRestless Legs Syndrome in patients with End Stage Renal Disease (ESRD)MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-003486-15-ATCB BIOSCIENCES GmbH48
进行中（未招募）
1 期
Study of efficacy and safety of LNP023 in primary IgA nephropathy patientsIgA NephropathyMedDRA version: 27.0Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-001049-38-SIovartis Pharma AG470
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure.Type 2 DiabetesEUCTR2008-005012-41-DEovartis Pharma Services AG246
进行中（未招募）
1 期
Study of efficacy and safety of LNP023 in primary IgA nephropathy patientsIgA NephropathyMedDRA version: 20.0Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-001049-38-FRovartis Pharma AG450